Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > See! I told you so...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Post by JDavenporton Dec 16, 2021 11:48am
282 Views
Post# 34237101

See! I told you so...

See! I told you so...

As I have stated over and over, Bioasis is super active on multiple fronts. It's clear from the AGM presentation and Q&A that I am correct about this.

It's not so nice to gloat but I've always known what xB3 is capable of and what its value could be. I also have been preaching about how proactive DrDR and the team have been.

The big surprise? Work with xB3-002. Wouldn't surprise me if Daiichi Sankyo AstraZeneca is involved in chasing neuro-oncology with Bioasis. I have written before about the possible connection between Daiichi Sankyo, AstraZeneca (AZ) and AZ's late, great subsidiary,  and ex-USA biotech, MedImmune.

Just a great and confirming presentation.

jd

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities